AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05695170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PreventT2 Together (Couple-based intervention)
Description: PreventT2 Together will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes and their partners. The curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevention type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
Study NCT05561699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab Combined With CRT
Description: 1. Penpulimab: 200mg, intravenous infusion, once every two weeks. After completing two courses of CRT, continue to send Penpulimab 200mg every two weeks on the first and 14th days after the completion of CRT, two courses of treatment, a total of four courses.~2. Radiotherapy 40gy/20fx, once a day from Monday to Friday, completed in 4 weeks;~3. PC regimen: Paclitaxel 50mg/m2, intravenous drip, carboplatin AUC=2mg/ml/min, intravenous drip, once a week during radiotherapy, a total of 4 courses, the specific time is D1, 8, 15, 22 days after the beginning of radiotherapy.~4. Gastrointestinal reactions such as nausea and vomiting should be routinely prevented before chemotherapy. Dexamethasone 10mg should be used 30 \~ 60 minutes before paclitaxel, and intramuscular injection should be stopped immediately in case of drug or infusion reactions.
Study NCT05687708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Nutritive Sucking
Description: NNS is stimulated by giving stimulus into the baby's mouth with the help of a finger wearing gloves.
Study NCT05137730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
Study NCT06300346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Ondansetron
Study NCT06322030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FOCUS-15 Lifestyle Management Program
Description: 15 week weight management program
Study NCT06322030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: 15 weeks of progressive exercise training
Study NCT04861519 — intervention group
Intervention type: OTHER
Intervention: Collecting invasive FFR measurements.
Description: Invasive FFR measurements from the patient's hospital records will be collected.
Study NCT06364397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP
Description: Participants will undergo ERCP and indomethacin will be administered rectally before procedure in participants with no known allergy to indomethacin. If the etiology of the participant is clearly defined during ERCP, the corresponding endoscopic treatment procedure will be performed. For others whose etiology are still unclear, pancreatic sphincterotomy and small caliber prophylactic pancreatic duct stent replacement will be performed. The participants will be observed closely after ERCP and record complications. Abdominal X-rays will be taken 2 weeks after ERCP to confirm spontaneous passage of the pancreatic duct stent, and the stent will be removed via gastroscopy if it still in place.
Study NCT06364397 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Health education and conservative management of clinical routines
Description: Participants will be given health education and conservative management of clinical routines. Clinical management is based on the pancreatic endocrine and exocrine function.
Study NCT06364397 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Health education and conservative management of clinical routines
Description: Participants will be given health education and conservative management of clinical routines. Clinical management is based on the pancreatic endocrine and exocrine function.
Study NCT05657535 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Low-intensity continuous ultrasound stimulator
Description: Stimulation 5 minutes, 3 times a day for 4 weeks on the knee
Study NCT04984512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitizodone Phosphate tablets
Description: Mitizodone Phosphate tablets will be administered with food.
Study NCT04984512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-matching tablets
Description: Placebo will be administered with food.
Study NCT05550896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogaphy
Description: Assessment of high velocity low amplitude signals on Doppler echocardiography
Study NCT06230835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Community Health Workers (CHWs) will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. CHWs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'. No any drugs will be used in the intervention group.
Study NCT05682846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium glycerophosphate pentahydrate solution
Description: Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml
Study NCT04763018 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iTEAR100
Description: Neurostimulation external nasal nerve to stimulate tear production
Study NCT04763018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTEAR100
Description: Neurostimulation external nasal nerve to stimulate tear production
Study NCT05042050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-iMAPS
Description: Imagery therapy targeting Psychosis-Related PTSD
Study NCT05215717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Hypnosis
Description: Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
Study NCT05215717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered White Noise Hypnosis
Description: Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
Study NCT06312189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study NCT05011253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Trigger Microhematuria Alert
Description: To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).
Study NCT04477460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Thickened feeds
Description: Thickened feeds directed by medical team
Study NCT04477460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Non-thickened feeds
Description: Non-thickened feeds directed by medical team
Study NCT06376370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of computer-assisted cognitive rehabilitation program
Description: Since the program will respond to the patient's specific needs, the activity may become easier or more difficult depending on the patient's performance. Epilepsy patients will be encouraged by researchers during the exercises and will be able to give feedback on progress at the end of the session. After determining the appropriate time and day for each patient in the experimental group, the intervention will continue for 6 weeks with 45-minute sessions once a week.
Study NCT05606978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FASTb
Description: FAST blended
Study NCT05606978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FASTr
Description: FAST regular
Study NCT05353868 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05085483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Ketogenic Supplement
Description: This trial has 5 steps: (1) a 4-week run-in baseline; (2) a 4-week intervention phase to either active or placebo (3) a 4-week phase of washout; (4) the cross-over to the second 4-week active or placebo phase; (5) a 4-week follow-up.
Study NCT05085483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric placebo supplement
Description: Isocaloric placebo supplement
Study NCT05229809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi Wenyang Jiedu prescription
Description: The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
Study NCT05229809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simulation agent of Yiqi Wenyang Jiedu prescription
Description: It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
Study NCT04665700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: BI 764198
Study NCT04665700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06304129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood ponction
Description: Blood ponction
Study NCT05251987 — intervention group
Intervention type: BIOLOGICAL
Intervention: PD1+ T Cell Expression
Description: The expression of PD1+ T cells was detected by flow cytometry in peripheral blood
Study NCT05604352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiaSole
Description: Diabetic ulcer offloading insole
Study NCT04784377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity laser in addition to traditional physical therapy exercises
Description: high intensity laser will be used with 1064 nm wavelength and maximum of 25 W power. Analgesic and biostimulant modes were used in the present study.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
Study NCT04784377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low level laser in addition to traditional physical therapy exercises
Description: patients will receive low level Laser Therapy in addition to traditional physical therapy exercises.~diode laser device with a wavelength of 850nm, power output of 100mV, continuous wave and 0.07cm2 spot area laser will be used. The laser will be applied with a dosage of 5 joule/cm2 (totally 15-20 joule) at the most 5 painful points for 1 minute at each point over subacromial region of the shoulder.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
Study NCT04784377 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional physical therapy exercises
Description: Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
Study NCT06045351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Intervention Group Initial 12 weeks;~* VD supplementation (600,000 IU I/M) once during the study period~* Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off~* Calcium 1000 mg/day
Study NCT06045351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Active Comparator (Group B; n=71):~Initial-- 12 weeks;~* Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks~* VD supplementation (600,000 IUI/M) once during the study period~* Calcium 1000 mg/day~* Standard PCOS Continued
Study NCT05163717 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INP105
Description: A single 5 mg dose of POD-OLZ (Precision Olfactory Delivery \[POD®\]-olanzapine)
Study NCT05289791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic activation of bioceramic sealer
Description: activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction
Study NCT05289791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasonic activation of bioceramic sealer
Description: activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction
Study NCT05163717 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of POD-placebo (Precision Olfactory Delivery \[POD®\]-placebo)
Study NCT05184985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueRelief device
Description: TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
Study NCT05184985 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TrueRelief device
Description: The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
Study NCT06100549 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be provided.
Study NCT06391944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101 Injection
Description: JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 or 21 days
Study NCT06391944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib tablet
Description: Osimertinib 80 or 160mg po everyday
Study NCT05657951 — intervention group
Intervention type: DEVICE
Intervention: ArcScan Insight 100 very high-frequency digital ultrasound
Description: The Insight-100 (ArcScan Inc., Golden, CO, USA) employs the high-frequency B-scan in the assessment of anterior segment parameters. Anormal saline coupling medium is formed with a disposable eyepiece between the 50 MHz transducer and the eye. The instrument moves the transducer in an arc so that the beam axis maintains approximate normality to the surface of the eye. The frequencies of cornea, anterior chamber, and lens are 60 MHz, 50 MHz and 50 MHz, respectively. The maximum arc scanning range is 70 degrees, and there is a linear scanning range of 29mm. The axial and lateral resolutions are 35 μm and 65 μm, respectively. It can measure structures behind the iris, including lens zonule.
Study NCT05354830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Massage
Description: Foot Massage
Study NCT05425693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid Warm-up
Description: Dynamic + stretching exercises
Study NCT05425693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Warm-up
Description: Dynamic exercises
Study NCT05425693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Warm-up
Description: Stretching exercises
Study NCT06204302 — intervention group
Intervention type: DRUG
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: Retrospective cohort analysis, using Komodo Research Database (KRD)
Study NCT06204302 — intervention group
Intervention type: DRUG
Intervention: Enzalutamide
Description: Retrospective cohort analysis, using Komodo Research Database (KRD)
Study NCT06204302 — intervention group
Intervention type: DRUG
Intervention: Apalutamide
Description: Retrospective cohort analysis, using Komodo Research Database (KRD)
Study NCT05752786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Less Meat Challenge
Description: Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
Study NCT05752786 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Eat Less Meat Challenge
Description: Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
Study NCT05984810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
Description: Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
Study NCT06165380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardenilimab Combined With Chemotherapy
Description: Cardenilimab Combined With Chemotherapy
Study NCT05955079 — intervention group
Intervention type: OTHER
Intervention: Whole blood
Description: 3 samples (before, after surgery and before chemotherapy)
Study NCT05431569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MW3211
Description: 6MW3211 injection ,30mg/kg,iv drip，Q2W
Study NCT04373785 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
Study NCT04373785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles.
Study NCT04373785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG101m
Description: Oral NG101m capsule continuously twice daily.
Study NCT05603754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorecivivint
Description: One intra-articular injection of 0.07 mg lorecivivint in 2 mL vehicle
Study NCT05603754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
Study NCT05594368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)
Description: Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.